Introduction
Papillomaviruses (PV) are small DNA tumour viruses which infect the epithelia of humans and animals causing benign hyperproliferative lesions. In most cases PV infections are cleared after several months following activation of the host immune system against viral antigen 1 . However, occasionally the lesions do not regress and can progress to cancer.
Certain PV are more commonly associated with malignancy, including the human PV (HPV) types 16 and 18, "high risk" viruses for the development of cervical cancer in women 2 , and bovine PV (BPV) type 4, associated with carcinomas of the alimentary canal in cattle 3 . Persistent viral infection is required for neoplastic progression and failure of virus clearance is attributed to a poor immunological response.
The PV genome encodes three transforming proteins, E5, E6 and E7. E5 is a small hydrophobic protein ranging in size from 42 amino acid residues in BPV-4 to 83 amino acid residues in HPV-16. E6 and E7 are the main transforming proteins of HPV 4, 5 ; E5 is the major transforming protein of BPV and plays a lesser role in transformation by HPV 6 . While E6 and E7 are expressed throughout the course of the disease and are necessary for the maintenance of a transformed phenotype, E5 is expressed only during the early stages of infection and its expression is often, but not always, extinguished as the lesion progresses toward malignancy 6 . These characteristics point to a role of E5 in establishment of PV infection and the initiation of cell transformation.
The E5 protein is localized in the Golgi apparatus (GA), endoplasmic reticulum and occasionally the plasma membrane of the host cell. Its localisation in the endomembrane compartments, where it interacts with the vacuolar ATPase 16k ductin/subunit c [7] [8] [9] , is deemed responsible for the lack of acidification of the GA and endo-lysosomes and the consequent impaired functions of these organelles 10, 11 . 4 We have shown that one of the outcomes of BPV E5 expression in primary cells is the retention of major histocompatibility (MHC) class I complexes in the GA and the inhibition of their transport to the cell surface 12, 13 . Furthermore, BPV E5 inhibits both transcription of the MHC class I heavy chain gene and affects the stability of the heavy chain protein 12 . In this study we show that HPV-16 E5 also prevents the transport of MHC (HLA) class I complexes to the cell surface due to retention in the GA. Moreover, we show that HPV-16 E5 selectively down-regulates HLA-A and HLA-B molecules on the cell surface but does not affect the transport of HLA-C and HLA-E. These studies identify a potential novel mechanism by which PV-infected cells may avoid clearance by cytotoxic T lymphocytes (CTL) and natural killer (NK) cells, aiding in the establishment and persistence of PV infection. HaCaT cells were stably transfected with 4 μg of pcDNA, pL2, pc-16E5 or pL2-16E5 per 1x10 6 cells using Lipofectamine Plus (Invitrogen) according to the manufacturer's instructions. Following transfection, the cells were selected in DMEM containing 500μg/ml G418 (Invitrogen) for 21 days. After this time, G418-resistant colonies were marked, individually picked and expanded into clonal cell lines for analysis.
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Materials and Methods
HPV
The retrovirus RT-16E5, or its empty counterpart (generated using wild-type pLZRSpBMLZ plasmid), was used to infect primary PalF cells as described 12 For the detection of intracellular MHC class I, the cells were first permeabilised with 0.5% saponin in PBS-B for 30 min at RT. Following a wash in PBS-B, the cells were then incubated with primary antibody as described above.
All samples were examined in a Beckman Coulter EPICS Elite analyser equipped with an ion argon laser with 15 mV of excitation at 488 nm. The data were analysed using Expo 2 software.
Immunofluorescence detection of MHC class I and GA.
In all experiments, HaCaT cells (1x10 
Results
Detection of E5 expression in cell lines
As E5 is expressed at very low levels in cells and there are no reliable antibodies against the protein, it is very difficult to detect its expression by immunoblotting 18 . Therefore we instead confirmed that the E5 ORF was being transcribed using quantitative RT-PCR.
Ten clones from each HaCaT cell transfection with pcDNA, pL2, pc-16E5 or pL2-16E5 were picked and expanded into cell lines for analysis. RNA was isolated and the relative level of prevents the HLA class I complex from reaching the cell surface, and retains it in the GA .
Expression of HLA class I heavy chain is not inhibited by HPV-16 E5
The results above suggested that, in contrast to BPV E5, HPV-16 E5 did not have any effect on the overall levels of the HLA class I heavy chain. To confirm this observation, we determined the relative levels of HLA class I in the control and E5-expressing HaCaT cell lines using mAb HC10, specific for the human HLA class I heavy chain 20 . Although the levels of HLA class I heavy chain were slightly lower in the pL2 and pL2-16E5 cell lines than in the pcDNA and pc-16E5 cell lines, there were no significant differences between the cells expressing HPV-16 E5 and their respective control cells (Figure 4 ), confirming that HPV-16 E5 does not down-regulate expression of the HLA class I heavy chain.
E5 has no effect on TAP expression. These experiments show that HPV-16 E5-expressing cells are responsive to IFN and that the E5-induced HLA class I transport inhibition is reversible by IFN.
HLA-C/E expression is not inhibited by HPV-16 E5
While MHC class I molecules HLA-A and -B are the main presenters of antigenic peptides to CTL, HLA-C and non-classical MHC molecules, such as HLA-E, inhibit NK cellmediated lysis by interacting with inhibitory NK receptors [24] [25] [26] . To determine whether HPV-16 E5 could selectively down-regulate HLA class I molecules, we determined the levels of HLA-C/E in parental, control and E5-expressing HaCaT cell lines. Cells were stained with mAb DT9 that recognises both HLA-C and -E, and were analysed by flow cytometry for surface and total HLA-C/E. Although the shift in forward fluorescence was small ( Figure   6A ,B), in agreement with the observation that human fibroblasts have little HLA-E 27 , it was consistently higher than background (secondary antibody only; Figure 6B ), and higher than the readings obtained with an unrelated antibody ( Figure 2C) ; Importantly, there were no significant differences between the control and E5-expressing cells ( Figure 6A ).
In addition, we determined the cellular localisation of HLA-C/E in the E5-expressing cells by immunofluorescence using mAb DT9. There were no differences between the staining patterns of HLA-C/E in the control cells and in the E5-expressing cells ( Figure 6C ), and therefore we conclude that expression of E5 does not lead to any appreciable decrease in surface HLA-C/E, in agreement with the FACS data.
Finally, we determined the levels of total HLA-E by immunoblotting with mAb MEM-E/02, specific for HLA-E. Similarly, we did not detect any significant differences between HLA-E levels in the control cells and the E5-expressing cells ( Figure 6D ).
The ease of HLA-C/E detection by immunofluorescence and immunoblotting compared with flow cytometry is likely attributable to the different affinities of the two antibodies for HLA (mAb DT9 and MEM-E/02) and to the greater sensitivity of mAb DT9 in immunofluorescence.
These results confirm that HPV-16 E5 down-regulates the surface expression of the classical HLA class I molecules HLA-A and -B, but not HLA-C or -E. We are unable to discriminate between HLA-C and HLA-E as mAb DT9 recognises both molecules, and mAb
MEM-E/02, specific for HLA-E, does not function in flow cytometry or immunofluorescence.
Discussion
Progression from acute HPV infection to malignancy requires persistence of virus, which in turn appears to depend on several factors, including the genetic background of the host 28, 29 , environmental co-factors 30 and the ability of the virus to avoid immune clearance 31 .
The immune system plays a decisive role in determining the clinical outcome of HPV disease, as demonstrated by the increased persistence and enhanced neoplastic progression of HPV infections in hosts with cell-mediated immune deficiencies 32, 33 . However, even in . Here we show that these properties are not a peculiarity of BPV E5 but are shared by E5
proteins of mucosal HPV, including E5 encoded by the low risk HPV type 6, the etiological agent of genital warts, and HPV-16, the papillomavirus most frequently associated with cervical carcinoma. Since our initial observations were published, it has also been reported However, given the selective down-regulation of HLA types by HPV-16 E5, the lack of GA acidification cannot be the whole explanation and other mechanisms must come into play.
These points are currently under investigation.
Despite the similarities, there are also differences between the extent to which BPV-4 E5
and HPV-16 E5 interfere with the MHC class I pathway. BPV-4 E5 down-regulates transcription of the MHC class I heavy chain gene, promotes degradation of the translated polypeptide and blocks the transport of the MHC class I complex to the cell surface 12, 13 . In contrast, HPV-16 E5 does not inhibit expression of the heavy chain, and reduces the transport of HLA class I to the cell surface without completely abolishing it. Furthermore, contrary to what we observed with BPV E5 13 , inhibition of HLA class I transport by HPV-16 E5 is reversible by IFN treatment. The reason for this latter difference is not known but it can be speculated that the increased production of HLA class I heavy chain by IFN is sufficient to overcome the inhibitory effect mediated by the low levels of HPV-16 E5. In contrast, as BPV E5 also inhibits transcription and promotes degradation of the MHC class I heavy chain 12 , IFN treatment is insufficient to restore MHC class I expression to normal levels. These data are also consistent with our hypothesis that there is a correlation between protein oncogenicity and immune evasion 38 . As discussed earlier, BPV E5 is a more effective transforming protein than HPV-16 E5 6 and therefore would be predicted to have a greater effect on MHC class I down-regulation (and other immune evasion mechanisms) than HPV-16 E5. In contrast, in oncogenic HPV infections, the two major transforming proteins E6 and This appears to be the case in bovine papillomas (our unpublished observations); HLA class I down-regulation has been observed in CIN 51 and in cervical carcinomas 52 . However the down-regulation of HLA class I in cervical carcinomas, which often do not express E5, is common to other cancer types, and therefore unlikely to be due to E5. No correlation was 
